Seviteronel: Ph I/II CLARITY data

Data from 17 evaluable patients with advanced breast cancer in the open-label, U.S. Phase I/II CLARITY (INO-VT-464-006) trial showed that once-daily 450 mg oral seviteronel led to 6 cases of stable di...